-

Automated Dried Spot Sampling and Analysis System Redefines Workflow

The Thermo Scientific Transcend DSX-1 integrated sample prep and ultra-high-performance liquid chromatography (UHPLC) system delivers high throughput, sensitive and compliant analysis

SAN JOSE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, enables clinical research, toxicology and anti-doping laboratories performing dried spot sampling and analysis to utilize a new automated sample prep and ultra-high-performance liquid chromatography (UHPLC) system to improve efficiency, robustness, sensitivity and sample traceability.

The new Thermo Scientific Transcend DSX-1 integrated sample prep and UHPLC system eliminates disc punching typically associated with dried matrix (spot) cards, and optimizes sample extraction and recovery of multiple matrices (e.g., blood, urine, serum and saliva). The new system enables laboratories performing routine analysis of drugs and other compounds to achieve substantial savings on time, labor and reagent costs compared to manual workflows. Proprietary flow-through desorption with heated capillary eliminates the need for manual, time-consuming extraction protocols and the automatic addition of an internal standard prior to the extraction minimizes matrix interference. Robustness and sensitivity are enhanced through online proprietary sample cleanup and enrichment via Thermo Scientific TurboFlow technology, producing confident results.

“Toxicology laboratories play a crucial role in detecting drug use and misuse in an ongoing struggle to safeguard society against increasing numbers of substances at ever decreasing concentrations. Dried spot analysis has emerged as a key technology in this area, requiring only a small amount of sample and, therefore, minimizing the user impact,” said Brad Hart, senior director, analytical vertical and life science mass spectrometry marketing, Thermo Fisher Scientific. “With the conventional workflow being held back by time-consuming manual procedures, we designed the Transcend DSX-1 system to ensure laboratories are able to effectively increase throughput to meet demand, while still ensuring the integrity and quality of results that are expected.”

Professor Mario Thevis, director for the Center for Preventative Doping Research, German Sport University, Cologne said, “Dried blood spot (DBS) tests have the potential to contribute substantially to an improved anti-doping testing program, today and in the future, supporting the clean athlete as well as the overall doping control analytical strategy. DBS analysis is the latest tool approved by the World Anti-Doping Agency (WADA) and was introduced at this year’s Winter Olympic Games in Beijing, China. In order to accommodate the specific needs associated with DBS analyses, and the considerable number of target analytes, robust, sensitive, programmable and especially automated DBS analytical options will offer critical advantages to anti-doping laboratories.”

The Transcend DSX-1 system is controlled by Thermo Scientific Aria MX software, which streamlines dried spot analysis by fully integrating all aspects of the workflow, such as:

  • Sample card handling
  • LC pump operation and valve switching
  • On-line sample clean-up
  • Liquid chromatography-tandem mass spectrometry methods

Furthermore, the Intelligent Vision Camera ensures data integrity and enables retrospective monitoring by capturing sample traceability, chain of custody and accurate spot recognition.

To find out more about the Transcend DSX-1 integrated sample prep and UHPLC system, please visit www.thermofisher.com/TranscendDSX.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

All rights reserved: Flow-through desorption (FTD).

Contacts

Media Contact Information:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Jess Grant
BioStrata
+1 315 420 0127
jgrant@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The Thermo Scientific Transcend DSX-1 is an integrated sample prep and UHPLC system for clinical research, toxicology and anti-doping laboratories.
Release Versions

Contacts

Media Contact Information:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Jess Grant
BioStrata
+1 315 420 0127
jgrant@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom